pharma · Obesity · Type 2 diabetes
NovoThirteen
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Company details
- Status
- Public
- HQ
- Bagsværd, JP
- Programs
- 94
- Drugs
- 67
- Patents
- 0
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Phase 1 · other · Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism for Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B). is a Phase 1 program (other) at NovoThirteen with 1 ClinicalTrials.gov record(s).
Internal code NN9388-8175
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NovoThirteen
- Phase
- Phase 1
- Modality
- other
- Indication
- Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).
- Status
- active
- Trials
- 1